This product can reduce capillary permeability, enhance the retraction effect of broken capillary ends, and increase the resistance of capillaries to damage. It is often used for various types of bleeding caused by increased capillary permeability.

It is broken down into diisopropylamine and dichloroacetic acid in the body. The former produces methionine, and the latter is metabolized to glycine. Under the action of glycine lyase, it produces N5N10-CH2-FH4 (methyltetrahydrofolate), which also provides energy and methyl to promote choline synthesis. Choline reacts with liver fat to produce lecithin, which promotes the decomposition of liver fat. It participates in the formation of lipoproteins and reduces fat accumulation in the liver.

No specific pharmacological effects were mentioned.

This product is a thromboxane synthetase inhibitor that can inhibit the production of TXA2, thus having the effects of anti-platelet aggregation and vasodilation. Animal experiments have shown that intravenous administration can reduce plasma TXB2 levels and the Keto-PGF12/TXB2 ratio, inhibit platelet aggregation caused by different inducers, and prevent cerebral infarction caused by the middle cerebral artery in rats.